AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
Company: AYTU BIOSCIENCE, INC. (Note: Filing header lists "AYTU BIOSCIENCE, INC." while metadata lists "AYTU BIOPHARMA, INC.")
Reporting Date: July 22, 2015
Event: Entry into a Material Definitive Agreement (Item 1.01) and Creation of a Direct Financial Obligation (Item 2.03).
The company closed a private placement of convertible promissory notes with institutional and high net worth individual investors. Newbridge Securities Corporation acted as the sole placement agent for the institutional portion.
Key Financial Metrics
- Capital Raised: $2.0 million in aggregate principal amount of convertible promissory notes.
- Target Offering Size: The company expects to raise up to a maximum of $6.0 million through this private placement, though no assurance is given.
- Placement Agent Fees: 8% of gross proceeds from notes sold by the agent, plus a warrant to purchase shares equal to 8% of those proceeds, and a $20,000 non-refundable retainer.
- Debt Instrument Terms:
- Maturity: January 22, 2017 (extendable by six months at company discretion).
- Interest Rate: 8% simple interest per annum for the first six months; 12% thereafter if not converted. Increases to 14% if a registration statement is not filed within six months.
- Conversion Price: $4.63 per share (subject to adjustment in Qualified Financing).
- Conversion Premium: 120% of principal and accrued interest.
- Liquidity: The filing does not provide current cash balance or liquidity metrics, only the proceeds from this specific transaction.
Material Changes and Use of Proceeds
This filing represents a material change in the company's capital structure through the issuance of new debt. The net proceeds are designated for:
- Conducting clinical studies for Zertane and RedoxSYS.
- Working capital to begin commercializing FDA-approved ProstaScint.
- General corporate purposes.
The company has agreed to file a registration statement on Form S-1 within five months of closing to register shares underlying the notes.
Outlook, Risks, and Contingencies
- Qualified Financing Trigger: Noteholders are obligated to convert if the company completes a public offering with at least $5.0 million in gross proceeds prior to maturity.
- Default Provisions: Notes are subject to acceleration upon customary events of default. If the S-1 is not filed within six months, interest rates increase, and notes held by officers/directors become subordinated.
- Liquidity Event: In the event of a sale of the company, noteholders may elect to receive principal plus accrued interest plus 25% of the original principal, or the consideration on an as-converted basis.
- Uncertainty: There is no assurance the company will be able to raise the remaining capital up to the $6.0 million target.
Investor Verification Checklist
- Verify the exact legal name of the registrant (AYTU BIOSCIENCE vs. AYTU BIOPHARMA) in subsequent filings.
- Confirm the filing of the Form S-1 registration statement within the required five-month window (by December 22, 2015).
- Monitor the company's ability to raise the remaining $4.0 million to reach the $6.0 million target.
- Review the specific terms of the "Qualified Financing" to understand potential dilution triggers.
- Check for any events of default that could trigger acceleration of the $2.0 million debt.